Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Cabozantinib and Pembrolizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma

NCT04442581 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04442581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Cabozantinib and Pembrolizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
April 20, 2021
Completion date
March 8, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma